[Review and revision of guidelines for ovarian cancer treatment in Japan].
A survey of members of the Japan Society of Gynecologic Oncology revealed that 93% of the members use the present Guideline for Ovarian Cancer Treatment in practice. There is an international consensus about first-line treatment for ovarian cancer. In contrast, the treatment for sex-cord stromal tumor, which is rare, and recurrent cancer are not standardized. In addition, management for borderline malignant tumor has been controversial. The new revision incorporates a new chapter regarding these matters. The revised Guideline may be more useful. We hope that re-examination and future revisions will be made to continually update the Guideline.
Kigawa
Junzo
J
Derpartment of Gynecologic Oncology, Tottori University, 36-1 Nishimachi, Yonago, Japan.
Katabuchi
Hidetaka
H
Yaegashi
Nobuo
N
D005260:Female; D006801:Humans; D007564:Japan; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012008:Recurrence; D011795:Surveys and Questionnaires